← Oncology Approval Tracker

FDA DECISION ·

Jubbonti

denosumab-bbdz · Sandoz

Biosimilar approvalBiosimilarBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Interchangeable Prolia biosimilar whose oncology-related uses increase bone mass in men at high fracture risk on androgen deprivation for nonmetastatic prostate cancer and women at high fracture risk on adjuvant aromatase inhibitor therapy for breast cancer.

LAMPGEN ANALYSIS

Why it matters

This presentation addresses treatment-associated bone loss in the specified patients, distinct from the Wyost indications.

What research teams should watch

Verify fracture risk, calcium and the oncology regimen, and keep the six-month dosing schedule separate from oncology-dose denosumab orders.

PRIMARY RECORDS

Sources